Our analysis not only provides genetics-driven support for repurposing CETP inhibitors to metabolic disease in the form of a CETP and SGLT2 inhibitor combination therapy, but also highlights the power of 2x2 factorial Mendelian Randomization as a framework through which combination therapies across disease verticals can be systematically discovered and mined for repurposing opportunities supported by human genetic validation. Here, SLC5A2 is linked to Other metabolic disease.